These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 28379384)
1. Osteocyte Protein Expression Is Altered in Low-Turnover Osteoporosis Caused by Mutations in WNT1 and PLS3. Wesseling-Perry K; Mäkitie RE; Välimäki VV; Laine T; Laine CM; Välimäki MJ; Pereira RC; Mäkitie O J Clin Endocrinol Metab; 2017 Jul; 102(7):2340-2348. PubMed ID: 28379384 [TBL] [Abstract][Full Text] [Related]
2. Teriparatide Treatment in Patients With WNT1 or PLS3 Mutation-Related Early-Onset Osteoporosis: A Pilot Study. Välimäki VV; Mäkitie O; Pereira R; Laine C; Wesseling-Perry K; Määttä J; Kirjavainen M; Viljakainen H; Välimäki MJ J Clin Endocrinol Metab; 2017 Feb; 102(2):535-544. PubMed ID: 27732335 [TBL] [Abstract][Full Text] [Related]
3. Biomarkers in WNT1 and PLS3 Osteoporosis: Altered Concentrations of DKK1 and FGF23. Mäkitie RE; Kämpe A; Costantini A; Alm JJ; Magnusson P; Mäkitie O J Bone Miner Res; 2020 May; 35(5):901-912. PubMed ID: 31968132 [TBL] [Abstract][Full Text] [Related]
4. Bone material properties and response to teriparatide in osteoporosis due to WNT1 and PLS3 mutations. Fratzl-Zelman N; Wesseling-Perry K; Mäkitie RE; Blouin S; Hartmann MA; Zwerina J; Välimäki VV; Laine CM; Välimäki MJ; Pereira RC; Mäkitie O Bone; 2021 May; 146():115900. PubMed ID: 33618074 [TBL] [Abstract][Full Text] [Related]
5. New Genetic Forms of Childhood-Onset Primary Osteoporosis. Kämpe AJ; Mäkitie RE; Mäkitie O Horm Res Paediatr; 2015; 84(6):361-9. PubMed ID: 26517534 [TBL] [Abstract][Full Text] [Related]
6. A novel splice mutation in PLS3 causes X-linked early onset low-turnover osteoporosis. Laine CM; Wessman M; Toiviainen-Salo S; Kaunisto MA; Mäyränpää MK; Laine T; Pekkinen M; Kröger H; Välimäki VV; Välimäki MJ; Lehesjoki AE; Mäkitie O J Bone Miner Res; 2015 Mar; 30(3):510-8. PubMed ID: 25209159 [TBL] [Abstract][Full Text] [Related]
7. Lipocalin-2 is associated with FGF23 in WNT1 and PLS3 osteoporosis. Loid P; Hauta-Alus H; Mäkitie O; Magnusson P; Mäkitie RE Front Endocrinol (Lausanne); 2022; 13():954730. PubMed ID: 36157448 [TBL] [Abstract][Full Text] [Related]
8. Altered Osteocyte-Specific Protein Expression in Bone after Childhood Solid Organ Transplantation. Pereira RC; Valta H; Tumber N; Salusky IB; Jalanko H; Mäkitie O; Wesseling Perry K PLoS One; 2015; 10(9):e0138156. PubMed ID: 26390291 [TBL] [Abstract][Full Text] [Related]
9. Osteoporosis caused by mutations in PLS3: clinical and bone tissue characteristics. Fahiminiya S; Majewski J; Al-Jallad H; Moffatt P; Mort J; Glorieux FH; Roschger P; Klaushofer K; Rauch F J Bone Miner Res; 2014 Aug; 29(8):1805-14. PubMed ID: 24616189 [TBL] [Abstract][Full Text] [Related]
10. Plastin 3 influences bone homeostasis through regulation of osteoclast activity. Neugebauer J; Heilig J; Hosseinibarkooie S; Ross BC; Mendoza-Ferreira N; Nolte F; Peters M; Hölker I; Hupperich K; Tschanz T; Grysko V; Zaucke F; Niehoff A; Wirth B Hum Mol Genet; 2018 Dec; 27(24):4249-4262. PubMed ID: 30204862 [TBL] [Abstract][Full Text] [Related]
11. Unique, Gender-Dependent Serum microRNA Profile in PLS3 Gene-Related Osteoporosis. Mäkitie RE; Hackl M; Weigl M; Frischer A; Kämpe A; Costantini A; Grillari J; Mäkitie O J Bone Miner Res; 2020 Oct; 35(10):1962-1973. PubMed ID: 32453450 [TBL] [Abstract][Full Text] [Related]
12. PLS3 Mutations in X-Linked Osteoporosis: Clinical and Bone Characteristics of Two Novel Mutations. Kannu P; Mahjoub A; Babul-Hirji R; Carter MT; Harrington J Horm Res Paediatr; 2017; 88(3-4):298-304. PubMed ID: 28605746 [TBL] [Abstract][Full Text] [Related]
13. PLS3 mutations in X-linked osteoporosis with fractures. van Dijk FS; Zillikens MC; Micha D; Riessland M; Marcelis CL; de Die-Smulders CE; Milbradt J; Franken AA; Harsevoort AJ; Lichtenbelt KD; Pruijs HE; Rubio-Gozalbo ME; Zwertbroek R; Moutaouakil Y; Egthuijsen J; Hammerschmidt M; Bijman R; Semeins CM; Bakker AD; Everts V; Klein-Nulend J; Campos-Obando N; Hofman A; te Meerman GJ; Verkerk AJ; Uitterlinden AG; Maugeri A; Sistermans EA; Waisfisz Q; Meijers-Heijboer H; Wirth B; Simon ME; Pals G N Engl J Med; 2013 Oct; 369(16):1529-36. PubMed ID: 24088043 [TBL] [Abstract][Full Text] [Related]
14. Altered MicroRNA Profile in Osteoporosis Caused by Impaired WNT Signaling. Mäkitie RE; Hackl M; Niinimäki R; Kakko S; Grillari J; Mäkitie O J Clin Endocrinol Metab; 2018 May; 103(5):1985-1996. PubMed ID: 29506076 [TBL] [Abstract][Full Text] [Related]
15. Skeletal Characteristics of WNT1 Osteoporosis in Children and Young Adults. Mäkitie RE; Haanpää M; Valta H; Pekkinen M; Laine CM; Lehesjoki AE; Schalin-Jäntti C; Mäkitie O J Bone Miner Res; 2016 Sep; 31(9):1734-42. PubMed ID: 27005318 [TBL] [Abstract][Full Text] [Related]
16. PLS3 sequencing in childhood-onset primary osteoporosis identifies two novel disease-causing variants. Kämpe AJ; Costantini A; Mäkitie RE; Jäntti N; Valta H; Mäyränpää M; Kröger H; Pekkinen M; Taylan F; Jiao H; Mäkitie O Osteoporos Int; 2017 Oct; 28(10):3023-3032. PubMed ID: 28748388 [TBL] [Abstract][Full Text] [Related]
17. Defective WNT signaling associates with bone marrow fibrosis-a cross-sectional cohort study in a family with WNT1 osteoporosis. Mäkitie RE; Niinimäki R; Kakko S; Honkanen T; Kovanen PE; Mäkitie O Osteoporos Int; 2018 Feb; 29(2):479-487. PubMed ID: 29147753 [TBL] [Abstract][Full Text] [Related]